

MicroPort Scientific Corporation


2023 Interim Results

August 2023



Contents

- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix Financial Statements



Partnerships with global leading KOLs and MedTech firms

Unswervingly invested in R&D for 25 years

Global leading medical devices company

Uncompromising in quality and relentless pursuit of excellence

Industry leading commercialization capabilities

Building a super -conglomerate of people centric enterprises of
EMERGING MEDICAL TECHNOLOGIES

1H23 Highlights



Newly obtained

- Global sales YOY, achieved remarkable growth of accessories
Non-China revenue YOY (Asia Pacific , South America), sales and distribution channel covered 73 countries/ regions
- China revenue YOY, robust sales growth of 1st MRI domestic pacemaker
Non-China 2.3% YOY (EEMEA 73%, AP 63%), rapid growth of Bluetooth® pacemakers (49% YOY) and ICDs (13% YOY)
- Revenue YOY (implantation ~46%); GPM +2 pts (66.1%), significant enhancement seen in operating efficiency
Overseas sales YOY, smoothly progressing CE registration
- Revenue YOY, net profit YOY, 3D navigation cases YOY,
TOP 1 Chinese player with 40,000+ 3D cases performed accumulatively
- China YOY (Castor®, Minos®, Reewarm® PTX)
Non-China revenue YOY, innovative products covered 28 overseas markets across EU, South America and Asia
- Revenue YOY, significant enhancement in operating profit (505.2% YOY), turnaround in net profit
Four products successfully commercialized in 12 countries/ regions overseas
- Revenue YOY, Toumai® completed 4 commercial installation , obtained multiple bidding orders for in Top-tier hospitals, installation on-track
Completed 1,200+ / 600+ human clinical surgeries for Toumai® 6NDCHU

V

Global Strategic Triangle






Contents


- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix Financial Statements

USD: million


■ 1H22
■ 1H23



Non-China business




China business




Business overview

1H23 revenue \$104.2mn, up 7.7% YOY , strong revenue growth disrupted by supply chain issue since March, significant recovery seen in July;
Accomplished **~19% growth in volume** as prior year, becoming the highest sales volume ever achieved, despite supply challenges globally;
Knee sales **up 16% YOY**, thanks to the growing popularity of Medial Pivot design, as well as synergy with SkyWalker™;
Completed FDA 510 (k) submission for Evolution® Hinge knee joint system and Procotyl® P Acetabular Cup;
Global manufacturing collaboration in progress, multi-projects in execution.


USD




Top 1
Chinese player
No. 1
market share for
China-made products



■ newly approved for marketing





China

1H23 revenue \$40.5mn, up 46.4% YOY, with significant enhancement seen in profitability;

Market access : newly entered 200+ hospitals, total coverage reached 2,800+ ZKHUHQ (DJG 6ZDQZV SURJUD HQNHG 100+ hospitals, covered ~700 hospitals in 200+ lower-tier;

Product sales : thanks to continuous market penetration, maintained strong sales growth of Tubridge®; NUMEN® & Bridge® & U-track® gained fast-growing market share; rapid market entry of Neurohawk® & Diveer®;

Registration: 4 NMPA approvals & 3 products submitted for NMPA , further enhanced AIS product portfolio, create integrated and diversified neurovascular disease solution with 17 commercialized products.



Non-China

International business generated revenue of \$2.1mn, up 27.3% YOY;


Four products successfully commercialized in 12 countries/ regions, covering half of the countries ranking top 10 worldwide by volume; NUMEN® completed 1st commercial implantations in 5 countries, newly approved in 4 countries;

U-track® completed 1st batch of commercial use in Brazil;

Tubridge® & Fastrack® obtained market approval in Argentina.

	Product	Pre-clinical	Clinical	Registration
Hemorrhagic Stroke	Tubridge Plus® Flow-diverting Stent			Completed enrollment of registration trial
	Comaneci® Embolization Assist Device*			CE marked & FDA cleared FDA Breakthrough Device Designation Design validation stage
	Rebridge® Intracranial Visualized Stent			Design validation stage
	Liquid Embolic Agent			Design validation stage
ICAD	Intracranial Drug-Coated Balloon Catheter System			Design validation stage
Acute Ischemic Stroke	Tigertriever® Revascularization Device*			✓ NMPA approved & CE marked & FDA cleared
	W-track® Intracranial Aspiration Catheter			✓ NMPA approved
	Balloon Guide Catheter			Submitted for NMPA review
	Neurohawk® Stent Thrombectomy Device 2			Submitted for NMPA review
	Tigertriever® 13 Revascularization Device*			FDA cleared Design validation stage
Accessories	Q-track® Microcatheter			✓ NMPA approved
	Veronwire™ Neurovascular Guide Wire			✓ NMPA approved
	Distal Protection Device			Submitted for NMPA review

Business highlights




1H23 revenue \$24.1mn, **up 38.4% YOY**, implantations **up ~46% YOY**, market share rises in top centers, penetrate continues in primary market; Gross profit margin maintain improving trend, up 2 ppts as compared with 1H22, significantly improvement also seen in operation efficiency; Successfully entered ~70 centers, hospital coverage reached 500+, single-center implantation increased by **8 ppts**; AccuSniper **✓ NMPA approved**; Smoothly progressing FIM study of self-developed TMVR system, one-year follow-up shows significant MR reduction with no recurrence, notable improvement of cardiac function, and quality of life; VitaFlow® III completed design freeze, expected NMPA submission in Q4.



Strong revenue growth out of China, up **243.1% YOY**, leverage on strong sales channel of Cardiovascular business, TAVI procurement increased rapidly since launched in South America; Successfully entered 60+ hospitals overseas, conducted 100+ commercial implantations accumulatively; **\$1.5M** & registration, expected to be the 1st Chinese TAVI product with CE mark

	Product	Pre-clinical	Clinical	Registration
TAVI	VitaFlow Liberty®			Approaching CE registration
	VitaFlow® III			Approaching Design freeze
	VitaFlow® Novo Generation			Design stage
	VitaFlow® Balloon Expandable			Animal studies
Access	AccuSniper Double Layer Balloon Catheter			✓ NMPA approved
	Expandable Sheath			Design stage
TMV	Self-developed replacement product			Progressing FIM studies
	Self-developed edge to edge repair product			Animal studies
	AltaValve - replacement product			Approaching EFS Completion
	\$PHQ - repair product			Progressing EFS
TTV	Self-developed replacement product			Design Stage
	Self-developed edge to edge repair product			Design stage
	Replacement product - partnership with 4C			Design stage



Business highlights



Business overview

1H23 revenue \$4.9mn, **up 3,110.2%** YOY, recorded robust sales growth for all marketed products, achieved breakthrough in globalization; Toumai® maintain leading position, market share rises simultaneously, completed **4** commercial installations, and won bids in top-tier hospitals; Cumulatively completed 1,200+ human clinical surgeries for Toumai®, and 600+ robot-assisted minimally-invasive surgical procedures for Toumai®.






Research & Development

Clinical developments
Laparoscopic: Toumai® Single-arm kick-off enrollment for registration trial;
Orthopedics: 6N: DOHU HQW LQW FQW YDQV RQW UHURU7RDO-LS Arthroplasty and Unicompartmental Arthroplasty;
Percutaneous: Mona Lisa obtained NMPA approval, become the 1st prostate puncture robot obtained the approval in the field of urology in China;
Panvascular: progressing registration for R-ONE, to obtain NMPA in 2023;
Natural orifice: conducting clinical trial for Trans-bronchial Surgical Robot.
5G remote surgeries
Over **50** 5G remote surgeries completed by surgical robots portfolio; created numerous records of **1st remote surgery in China and globally**; R-ONE successfully completed **1st** robot-assisted 5G ultra-remote PCI surgery crossing a distance of 2,800 kilometers in July.



Globalization

Overseas registration
DFVision® obtained CE mark;
6N: DOHU REVDLQHP DUHVDSSURYDQW LDDG\$ XWDD
Toumai® submitted application for the CE mark.
Commercialization
Thanks to strong synergy with Medial-3LYRW QH 6N: DOHU WSLGO deploying installation and commercialization in the US, actively exploring market opportunities worldwide.

	Product	Pre-clinical	Clinical	Registration
Laparoscopic	Toumai® Laparoscopic Surgical Robot ("Toumai®")		✓ Obtained NMPA CE marking in progress	
	Toumai® 2 nd Generation		Submitted for NMPA review	
	Toumai® Single-arm Laparoscopic Surgical Robot		Started enrollment of registration trial	
Orthopedic	Skywalker™ Orthopedic Surgical Robot		✓ Obtained NMPA approval ✓ Obtained FDA & CE & ANVISA & TGA approval	
	Spine Surgical Robot		Design validation stage	
Natural Orifice	Trans-bronchial Surgical Robot		Started enrollment of registration trial	
Panvascular	R-ONE® Vascular Interventional Surgical Robot		NMPA registration on progress Obtained CE in 2019	
	TAVR Surgical Robot		Design development stage	
Percutaneous	Transperineal Prostate Biopsy System ("Mona Lisa")		✓ Obtained NMPA approval Obtained CE & FDA in 2017	
	Thoracic and Abdominal Puncture Robot		Design validation stage	

 Product admitted in NMPA Green Path

 Note: 1. for the indication in percutaneous nephrolithotomy



Business overview

Provide systematic life support solutions for acute critical cases ;
1H23 revenue \$3.1mn, up 39.4% YOY, thanks to rapid overseas sales of oxygenators, smoothly promoting hospital entry of Vitasprings IQ&KLD femoral cannula series obtained NMPA approval, become the 1st China-developed TPU Femoral Cannula to go to market.



Product overview

19

received









received

Flagship MOBYBOX ECMO System

1st fully integrated ECLS system to provide both blood flow and gas management in a single device, obtained CE mark under MDR regulation; Leverage on diversified portable design, aiming to forge movable critical care unit focusing on pre-hospital emergency care.



Globalization

	Product	Pre-clinical	Clinical	Registration
Emergency transport system	Hemovent ¹ MOBYBOX [®] ECMO 	✓ Obtained CE mark		
	Hemovent ¹ MOBYO [™] ECMO Oxygenator	✓ Obtained CE mark		
	Hemovent ¹ WATCHA Blood Oxygen Saturation Monitoring Sensor	✓ Obtained CE mark		
ECMO	Centrifugal ECMO system		Approaching Animal studies	
	Double lumen cannula		Approaching Animal studies	
	Transseptal cannula		Design stage	
CPB	9 INVSUQJV 0 HP EUDGH 2 \ JHODRU	✓ Obtained NMPA approval		
	Cannula series	✓ Obtained NMPA approval & CE mark		
	FILAVENT Femoral Cannula series	✓ Obtained NMPA approval		
	MOBYO [™] ECMO Oxygenator		Animal studies	
Congenital heart diseases	Atrial Septal Defect Occluder 	✓ Obtained NMPA approval		
	Patent Ductus Arteriosus Occluder 	✓ Obtained NMPA approval		
	Ventricular Septal Defect Occluder 	✓ Obtained NMPA approval		
	Occluder delivery system	✓ Obtained NMPA approval		
Others	Patient monitoring system	Data processing platform	ICU management	Heart failure
				In-hospital transport system

 Product admitted in NMPA Green Path

	Product	Indication	Pre-clinical	Clinical	Registration
OCT	Insight-100 ArgusClarity	PCI	✓ Obtained NMPA approval		
	Insight-100 1350 NOPURGE (OCT catheter)	PCI	✓ Obtained NMPA approval		
	Insight-100h High Speed OCT	PCI	✓ Obtained NMPA approval		
	High Resolution OCT	PCI		Type testing stage	
	Peripheral/Intracranial OCT	Panvascular			
Multi-module interventional	Soul-Man DSA System	Interventional	✓ Obtained NMPA approval		
	Coronary Artery IVUS	PCI		Type testing stage	
	Peripheral/Intracranial IVUS	Panvascular			
	IVUS-ICE	SHD			
	OCT+IVUS	PCI		Prototype development stage	
	OCT+IVUS+FFR	PCI			
MRI	Imported MRI System	Prostate biopsy	✓ Obtained FDA approval		
	Chinese MRI System	Prostate biopsy			

Business highlights

Provide innovative total solutions in endoscope and disposal devices to urological, gastrointestinal, gynaecological & respiratory diseases; 1H23 revenue up **190.0%** YOY, formed total-solution for Urinary Calculus
20 NMPA certificates & 3 CE marks obtained accumulatively;
Milestone progress obtained under the development of endoscopic imaging pipeline in digestive endoscope;
Closed strategic financing with RMB 140mn raised.

R&D progress

30+

in pipeline

1

Products obtained

Key product 1st in China, 2nd globally
6 PRMO SURJHMQ UJLVDRQWDRU Green Path product, Prostatic urethral lift system

Globalization

6

successfully commercialized in 4 countries/ regions

3

obtained CE mark in 2023

	Product	Indication	Pre-clinical	Clinical	Registration
Single-use endoscope	Single-use digital ureteroscope catheter	Urology	✓ Obtained NMPA approval		
	Single-use digital choledochoscope catheter	Gastroenterology	✓ Obtained NMPA approval		
	7 other candidates covering urological, gastrointestinal, gynecological and respiratory indications				
Reusable endoscope	3 candidates covering gastrointestinal and respiratory indications				
Passive consumables	Nephrostomy balloon dilation catheter		✓ Obtained NMPA approval		
	Single-use endoscopic retrieval basket (3 claws)		✓ Obtained NMPA & CE approval		
	Ureteral access sheath		✓ Obtained NMPA approval		
	Single-use urinary track guidewire	Urology	✓ Obtained NMPA & CE approval		
	Ureter balloon dilation catheter		✓ Obtained NMPA & CE approval		
	Prostatic urethral lift system		✓ Progressing registration trial		
	Hybrid zebra guidewire				
	Ultrathin basket				
Energy-based	Ruyi & CS VR1WVXFCS	Gastroenterology	✓ Obtained NMPA approval		
	6 other candidates covering gastrointestinal and urological indications				
	5 candidates covering general, gynecological and gastrointestinal indications				
Neuro modulation	3 candidates covering urological and respiratory indications				

 Product admitted in NMPA Green Path



Contents


2

3

00:00:06

Revenue

USD: million




Gross profit margin




Operating expenses

USD: million



Total net loss & net loss attributable to equity shareholders

USD: million



Sales & marketing expenses

Administrative expenses

R&D expenses





Sales & marketing expenses increased by 15.8% YOY



Contents

- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook**
- 5 Appendix Financial Statements

Innovative product pipeline fueling long-term growth

Cardio-vascular	Guide Catheter NMPA	Firesorb® Bioresorbable Scaffolds NMPA		Non-slip - element Balloon NMPA	Coronary Covered Stent NMPA	Coronary Rapamycin Drug - coated Balloon NMPA	Coronary Stent Graft System NMPA	Coronary Rotational Atherectomy System NMPA		Intravascular Lithotripsy Balloon NMPA		Firehawk® stent FDA	Pressure Guidewire NMPA
Orthopedics	Classic Profemur® Cemented XM® Femoral Stem FDA		Hinged Knee Joint System FDA		Evolution Tibia Cones FDA		2D-to-3D Imaging Technology FDA			Wrist Joint Prosthesis System NMPA		Procotyl P Acetabular Cup (Dual Mobility/ Revision) FDA	
CRM	Pacemaker (MRI) NMPA		BonaFire Passive Lead (MRI) NMPA		ENERGY/TALENTIA Bluetooth® ICD/CRT-D CE		Left Bundle Branch pacing lead CE	Pulsea Bluetooth® CRT-P CE	Space HP ICD/CRT-D NMPA	Invicta Lead NMPA			
Endo-vascular	Resuscitative Endovascular Balloon NMPA	Vflower® Venous Stent System NMPA		Peripheral PTA Balloon Catheter NMPA	Fibered Embolization Coil NMPA	Vewatch® Vena Cava Filter NMPA	Fishhawk Catheter NMPA	Cratos Branched Aortics Stent Graft System NMPA	Aegis® II Abdominal Aortic Stent Graft System NMPA	TIPS Stent Graft System NMPA			
Neuro-vascular	Comaneci® Embolization Assist Device NMPA	Balloon Protection Guide Catheter NMPA	Neurohawk® Stent Thrombectomy Device 2 NMPA		Tubridge Plus® Flow - diverting Stent NMPA	Tigertriever® 13 Revascular - ization Device* NMPA	Rebridge® Intracranial Visualized Stent NMPA	Intracranial Drug -Coated Balloon Catheter System NMPA		Liquid Embolic Agent NMPA			
Heart Valve	VitaFlow Liberty® CE	VitaFlow® III NMPA	Novo Generation NMPA	VitaFlow® Balloon Expandable NMPA	Expandable Sheath NMPA	Self-developed TMVR product NMPA	AltaValve TMVR Product NMPA	TMVr Product NMPA	Self-developed edge to edge repair product NMPA	TTV Self-developed replacement product/ Self-developed edge to edge repair/ Trivid			
Surgical Robot	R-ONE® Panvascular Surgical Robot NMPA			Skywalker™ Orthopedic Surgical Robot (Hip) NMPA		Toumai® Laparoscopic Surgical Robot CE		Toumai® Single -arm Laparoscopic Surgical Robot NMPA		Trans - bronchial Surgical Robot NMPA	TAVR Surgical Robot NMPA	Spine Surgical Robot NMPA	
Surgical Devices	Arterial Micro -Embolic Filter (new type) NMPA			Double lumen cannula NMPA		MOBYBOX System NMPA			Centrifuge ECMO NMPA		Transseptal cannula NMPA		
Electro - physiology ¹	Navigation System V4 NMPA			Flashpoint® Renal Artery Ablation Catheter NMPA		Renal RF Ablation System NMPA		Force -Sensing Pulse Field Ablation Catheter NMPA					



Contents

- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix Financial Statements

USD'000	2023 1H	2022 1H	Var.
Revenue	482,605	404,984	19.2%
Cost of sales	(194,189)	(157,282)	23.5%
Gross profit	288,416	247,702	16.4%
Other net income	17,039	41,356	-58.8%
Research and development costs	(187,334)	(186,430)	0.5%
Distribution cost	(169,800)	(146,610)	15.8%
Administrative expenses	(95,890)	(133,259)	-28.0%
Other operating costs	(12,374)	(8,328)	48.6%
Loss from operations	(159,943)	(185,569)	-13.8%
Finance cost	(37,256)	(46,050)	-19.1%
Gain on deemed disposal of a subsidiary	2,845	-	N/A
Gain on deemed disposal of interest in equity-accounted investees	5,437	1,920	183.2%
Share of losses of equity-accounted investees	(17,258)	(18,141)	-4.9%
Loss before taxation	(206,175)	(247,840)	-16.8%
Income tax	(13,746)	(5,435)	152.9%
Loss for the period	(219,921)	(253,275)	-13.2%
Attributable to: Equity shareholders of the Company	(162,618)	(198,130)	-17.9%

USD'000	30 June 2023	31 Dec 2022	Var.
Non-current assets			
Investment properties	6,315	6,579	-4%
Other property, plant and equipment	969,558	993,014	-2%
Intangible assets	223,215	223,683	0%
Goodwill	265,571	262,829	1%
Equity-accounted investees	407,214	423,873	-4%
Other financial assets	19,676	23,155	-15%
Deferred tax assets	27,893	27,637	1%
Other non-current assets	97,710	94,081	4%
Total non-current assets	2,017,152	2,054,851	-2%
Current assets			
Inventories	395,404	352,428	12%
Trade and other receivables	312,704	284,833	10%
Pledged deposits and time deposits	226,874	60,765	273%
Cash and cash equivalents	843,430	1,203,007	-30%
Derivative financial assets	36,874	38,201	-3%
Total current assets	1,815,286	1,939,234	-6%
Current liabilities			
Trade and other payables	367,557	380,554	-3%
Contract liabilities	24,146	22,598	7%
Lease liabilities	42,457	51,944	-18%
Interest-bearing borrowings	257,366	185,387	39%
Income tax payable	8,217	17,470	-53%
Convertible bonds	650,589	-	N/A
Derivative financial liabilities	5,755	4,172	38%
Total current liabilities	1,356,087	662,125	105%
Net current assets	459,199	1,277,109	-64%

USD'000	30 June 2023	31 Dec 2022	Var.
Non-current liabilities			
Interest-bearing borrowings	417,298	336,689	24%
Lease liabilities	103,828	124,373	-17%
Deferred income	34,068	38,123	-11%
Convertible bonds	98,083	769,553	-87%
Contract liabilities	24,721	24,839	0%
Other payables	233,392	220,997	6%
Deferred tax liabilities	24,305	24,718	-2%
Total non-current liabilities	935,695	1,539,292	-39%
CAPITAL AND RESERVE			
Share capital	18	18	-
Reserves	960,178	1,135,012	-15%
Total equity attributable to equity shareholders of the Company	960,196	1,135,030	-15%
Non-controlling interests	580,460	657,638	-12%
Total equity	1,540,656	1,792,668	-14%

